清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

814 DT-9081, a selective EP4receptor antagonist which synergizes with immune checkpoint inhibitors to induce complete responses in syngeneic murine cancer models

免疫系统 癌症研究 肿瘤微环境 结直肠癌 抗体 癌症 敌手 药理学 癌症免疫疗法 免疫疗法 受体 化学 医学 免疫学 内科学
作者
Anne‐Laure Blayo,Claire Jouffroy-Zeller,Nathalie Lenne,Imane Nafia,Patricia Zerr,Stéphan Schann,Xavier Leroy
出处
期刊:Journal for ImmunoTherapy of Cancer [BMJ]
卷期号:: A850-A850
标识
DOI:10.1136/jitc-2022-sitc2022.0814
摘要

Background Elevated levels of Prostaglandin E2 (PGE2), an eicosanoid synthesized by the cyclooxygenase-2 (COX-2), exert strong immunosuppressive effects in the tumor microenvironment (TME). COX-2-positive solid tumors have the ability to use this pathway as a resistance mechanism, especially to escape from the host immune system, thus limiting the anti-tumor effects of immune checkpoint inhibitors (ICI). These immunosuppressive effects are largely mediated by the EP4 receptor, expressed on multiple immune cells. DT-9081, a selective EP4 receptor antagonist, has been designed to counteract the PGE2-immunosuppressive effects in the TME and to synergize with ICI. Methods DT-9081 has been evaluated in 2 syngeneic murine cancer models in combination with ICI. DT-9081 was first tested at 30 and 60 mg/kg, as single agent or in combination with anti-CTLA-4 antibody, in the CT26 colorectal cancer model. DT-9081 was then tested at 30 mg/kg as single agent, or at 3, 10 or 30 mg/kg in combination with an anti-PD-1 in the MCA205 sarcoma model. In both studies, tumor growth, survival and type of response were evaluated. Complete responders were additionally submitted to a tumor rechallenge study to evaluate the immune system memory. Results In the CT26 colorectal cancer model, combination of DT-9081 at both doses with anti-CTLA-4 antibody enabled a significant tumor growth inhibition and a noticeable increase in survival as compared to the anti-CTLA-4 antibody treatment alone. Moreover, 3 and 2 complete responses over 10 mice were observed in the groups treated with 30-mg/kg and 60-mg/kg DT-9081 in combination with the anti-CTLA-4 antibody, compared to none in the anti-CTLA-4 antibody treatment alone group. In the MCA205 sarcoma model, combination of DT-9081 at the 3 tested doses with anti-PD-1 antibody enabled significant tumor growth inhibition and increase in survival, with a maximum anti-tumor efficacy from 10-mg/kg DT-9081. 5, 9 and 10 complete responses over 15 mice were observed in the groups treated with 3-, 10- and 30-mg/kg DT-9081, respectively, in combination with the anti-PD-1 antibody, compared to a single one in the anti-PD-1 antibody treatment alone group. Complete responders from both studies were additionally assessed to address their response to a new challenge with the corresponding tumor cells. No tumor growth was observed indicating a long lasting tumor immune control. Conclusions DT-9081 demonstrates strong anti-tumor effects in multiple syngeneic mouse tumor models, and synergizes with immune checkpoint inhibitors to induce long lasting complete responses. DT-9081 has completed regulatory development and will enter in clinical development by the end of 2022.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
迷你的蜜粉完成签到,获得积分10
13秒前
大个的应助被Gilgardea采纳,获得10
24秒前
汉堡包的应助被辅助但上分采纳,获得10
34秒前
忧郁凝阳完成签到,获得积分10
42秒前
整齐成协完成签到,获得积分10
47秒前
55秒前
冥土追魂完成签到,获得积分10
56秒前
冥土追魂发布了新的文献求助10
59秒前
丘比特的应助被武雨寒采纳,获得10
1分钟前
懵懂的小之完成签到,获得积分10
1分钟前
专注的怜珊完成签到,获得积分10
1分钟前
完美世界的应助被武雨寒采纳,获得10
1分钟前
科研通AI6.4的应助被cat采纳,获得10
1分钟前
1分钟前
羞涩的傲菡完成签到,获得积分10
1分钟前
武雨寒发布了新的文献求助10
1分钟前
兴奋乞完成签到,获得积分10
1分钟前
零度空间完成签到,获得积分10
1分钟前
痴情的不惜完成签到,获得积分10
1分钟前
1分钟前
整齐念薇完成签到,获得积分10
1分钟前
武雨寒发布了新的文献求助10
2分钟前
2分钟前
诸葛平卉完成签到 ,获得积分10
2分钟前
星辰大海的应助被psm采纳,获得10
2分钟前
2分钟前
飞天大南瓜完成签到,获得积分10
2分钟前
Gilgardea发布了新的文献求助10
2分钟前
车车完成签到 ,获得积分10
2分钟前
精明开山完成签到,获得积分10
2分钟前
2分钟前
鲤鱼遥完成签到,获得积分10
2分钟前
cat发布了新的文献求助10
2分钟前
AG完成签到,获得积分10
2分钟前
田田完成签到 ,获得积分10
2分钟前
2分钟前
等待凡英完成签到,获得积分10
2分钟前
陈荆洲完成签到,获得积分10
2分钟前
高高的玉兰完成签到,获得积分10
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166413
求助须知:如何正确求助?哪些是违规求助? 9559494
关于积分的说明 21750478
捐赠科研通 7757221
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553489
邀请新用户注册赠送积分活动 2473835